Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/00048674241276700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
British contributions to the therapeutic use of John Cade's lithium.
Br J Psychiatry
September 2024
Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; and CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, New South Wales, Australia.
Article Synopsis
- The text talks about the 75th anniversary of a important paper by John Cade, who discovered that lithium can help treat people with manic episodes.
- It mentions that there was other important research in Britain that supported Cade's findings about lithium.
- However, some British experts had opinions that might have stopped lithium from being used in medical treatments for some time.
John Cade's lithium: A granular look at his achievement.
Aust N Z J Psychiatry
September 2024
Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
A History of the Pharmacological Treatment of Bipolar Disorder.
Int J Mol Sci
July 2018
Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health Sciences, University of Alcalá, Crta. de Madrid-Barcelona, Km. 33,600, 28871 Alcalá de Henares, Madrid, Spain.
In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agents introduced in the 19th and early 20th century, such as solanaceae alkaloids, bromides and barbiturates, to John Cade's experiments with lithium and the beginning of the so-called "Psychopharmacological Revolution" in the 1950s. We also describe the clinical studies and development processes, enabling the therapeutic introduction of pharmacological agents currently available for the treatment of bipolar disorder in its different phases and manifestations. Those drugs include lithium salts, valproic acid, carbamazepine, new antiepileptic drugs, basically lamotrigine and atypical antipsychotic agents (olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, asenapine, cariprazine and lurasidone).
View Article and Find Full Text PDFCade's identification of lithium for manic-depressive illness--the prospector who found a gold nugget.
J Nerv Ment Dis
December 2012
Mental Health Research Institute, University of Melbourne, Melbourne, Australia.
John Cade's identification of lithium as a treatment of manic-depressive illness has been judged as a landmark biomedical advance and as an initiator of modern psychopharmacology. His personal background, interests, character, experiences, and key observational skills are sketched to provide the background and logic for his discovery and to argue against his simple self-description as a clinician administrator. The Cade story illustrates the potential strengths of clinical research whereby the clinician observes "signals," formulates hypotheses and explanations, and then pursues or encourages their validity and application.
View Article and Find Full Text PDFAdvancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine.
Psychopharmacol Bull
January 2004
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
The last half of the 20th century witnessed remarkable advances in the field of psychiatry that began with serendipity and were realized through the combined efforts of astute clinical observation, scientific investigation, and patient advocacy. The modern era of psychopharmacology of mood disorders began in the late 1940s with John Cade's discovery of the mood-stabilizing properties of lithium.1 Less than 5 years later came the unexpected observation of elevated mood and activation among patients on a tuberculosis ward who were treated with the antitubercular agent, iproniazid.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!